Asia-Pacific API Intermediates Market - Industry Trends and Forecast to 2028

TABLE OF CONTENT

TABLE OF CONTENTS 1 INTRODUCTION 1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF ASIA-PACIFIC API INTERMEDIATES MARKET 1.4 LIMITATIONS 1.5 MARKETS COVERED 2 MARKET SEGMENTATION 2.1 MARKETS COVERED 2.2 GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 CURRENCY AND PRICING 2.5 DBMR TRIPOD DATA VALIDATION MODEL 2.6 MULTIVARIATE MODELLING 2.7 TYPE LIFELINE CURVE 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.9 DBMR MARKET POSITION GRID 2.10 VENDOR SHARE ANALYSIS 2.11 MARKET TYPE COVERAGE GRID 2.12 SECONDARY SOURCES 2.13 ASSUMPTIONS 3 EXECUTIVE SUMMARY 4 PREMIUM INSIGHT 4.1 CURRENT SCENARIO OF IMPORT AND EXPORT OF API INTERMEDIATE 4.2 TENTATIVE PRODUCTION AND OPERATIONAL COSTS CALCULATIONS WHICH WILL ULTIMATELY LEAD TO FEASIBILITY OF THE PRODUCT MANUFACTURING 4.2.1 TENTATIVE LAND REQUIREMENT FOR A SUBSTANTIAL PRODUCTION CAPACITY PLANT SET-UP 4.3 ASIA-PACIFIC API INTERMEDIATES MARKET: 3C ANALYSIS-CHINA EFFECT 4.3.1 THE U.S.-CHINA TRADE WAR 4.3.2 INDO-CHINA GEOPOLITICAL ISSUES 4.3.3 CHINESE SLOWDOWN DUE TO E&C OVER THE YEARS 4.3.4 CHINESE SLOWDOWN DUE TO COVID-19 (CORONAVIRUS) 4.4 COST ANALYSIS 4.5 ANALYSIS ON CHINA API INTERMEDIATES: 4.5.1 CONCLUSION: 4.6 PORTERS FIVE FORCES MODEL 4.7 PESTEL ANALYSIS 4.8 ASIA-PACIFIC API INTERMEDIATES MARKET: REGULATORY 4.8.1 THE U.S. REGULATORY GUIDANCE FOR NON-CLINICAL SAFETY EVALUATION OF API INTERMEDIATES 4.8.2 CANADA REGULATORY GUIDANCE FOR API INTERMEDIATES 4.8.3 EUROPE REGULATORY SCENARIO FOR API INTERMEDIATES 4.8.4 JAPAN REGULATORY FOR API INTERMEDIATES 4.8.5 MIDDLE EAST AND AFRICA REGULATORY FRAMEWORK FOR API INTERMEDIATES 5 ASIA-PACIFIC API INTERMEDIATES MARKET: CONCLUSION 5.1 TOP PRODUCTS AND THERAPEUTIC AREAS 5.2 ADDITIONAL 6 CUSTOMER SENTIMENTS/INCLINATION TOWARDS FINDING ALTERNATE VENDOR SOURCE 7 LIST OF API OR FORMULATION COMPANIES WITH API INTERMEDIATE: 8 MARKET OVERVIEW 8.1 DRIVERS 8.1.1 HIGH BURDEN OF CHRONIC DISEASES 8.1.2 INCREASE IN AGING POPULATION 8.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING 8.1.4 INCREASING DISEASE AWARENESS AND EDUCATION 8.1.5 RESEARCH AND DEVELOPMENT REGARDING PHARMACEUTICAL API AND THEIR INTERMEDIATES 8.2 RESTRAINTS 8.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS 8.2.2 PRODUCT RECALLS 8.2.3 HIGH MANUFACTURING COST 8.2.4 STRINGENT GOVERNMENT REGULATIONS FOR API INTERMEDIATES 8.3 OPPORTUNITIES 8.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 8.3.2 INCREASING HEALTHCARE EXPENDITURE 8.3.3 SOARING NUMBER OF API INTERMEDIATES MANUFACTURERS 8.3.4 RISE IN NUMBER OF CONTRACT MANUFACTURING ORGANIZATIONS (CMO) AND CONTRACT RESEARCH ORGANIZATIONS (CRO) 8.4 CHALLENGES 8.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19 8.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES 9 IMPACT OF COVID 19 ON ASIA-PACIFIC API INTERMEDIATES MARKET 9.1 IMPACT ON PRICE 9.2 IMPACT ON DEMAND 9.3 IMPACT ON SUPPLY CHAIIN 9.4 STRATEGIC DECISIONS FOR MANUFACTURERS AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE 9.5 CONCLUSION 10 ASIA-PACIFIC API INTERMEDIATES MARKET, BY TYPE 10.1 OVERVIEW 10.2 PHARMACEUTICAL INTERMEDIATES/ BULK DRUG INTERMEDIATES 10.3 VETERINARY DRUG INTERMEDIATES 11 ASIA-PACIFIC API INTERMEDIATES MARKET, BY PRODUCT 11.1 OVERVIEW 11.2 NITRILES 11.3 BROMO COMPOUND 11.4 CHIRAL PCBHP 11.5 CHLORPHENIRAMINE BASE 11.6 BROMPHENIRAMINE BASE 11.7 PHENIRAMINE BASE 11.8 O-BENZYL SALBUTAMOL 11.9 BISOPROLOL BASE 11.10 HEMISULFATE 11.11 OXIRANE 11.12 MEPYRAMINE/PYRILAMINE BASE 11.13 THEOFYLLINE 11.14 ACEFYLLINE 11.15 XANTHINE 11.16 6-AMINO-1,3-DIMETHYL URACIL 11.17 OTHERS 12 ASIA-PACIFIC API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE 12.1 OVERVIEW 12.2 CARDIOVASCULAR DISEASES 12.3 METABOLIC DISEASES 12.4 INFECTIOUS DISEASES 12.5 RESPIRATORY DISEASES 12.6 NEUROLOGY 12.7 ONCOLOGY 12.8 AUTOIMMUNE DISEASE 12.9 DERMATOLOGY 12.10 OPHTHALMOLOGY 12.11 UROLOGY 12.12 OTHERS 13 ASIA-PACIFIC API INTERMEDIATES MARKET, BY CUSTOMERS 13.1 OVERVIEW 13.2 DIRECT USERS/PHARMA COMPANIES 13.3 TRADERS/WHOLESALERS/DISTRIBUTORS 13.4 ASSOCIATIONS/GOVT. INSTITUTIONS/PVT INSTITUTIONS 14 ASIA-PACIFIC API INTERMEDIATES MARKET, BY END USER 14.1 OVERVIEW 14.2 API MANUFACTURER 14.3 FINISHED PRODUCT MANUFACTURER 15 ASIA-PACIFIC API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL 15.1 OVERVIEW 15.2 DIRECT TENDER 15.3 RETAIL SALE 15.4 OTHERS 16 ASIA-PACIFIC API INTERMEDIATES MARKET BY GEOGRAPHY 16.1 ASIA-PACIFIC 16.1.1 CHINA 16.1.2 INDIA 16.1.3 JAPAN 16.1.4 AUSTRALIA 16.1.5 SOUTH KOREA 16.1.6 SINGAPORE 16.1.7 MALAYSIA 16.1.8 THAILAND 16.1.9 INDONESIA 16.1.10 PHILIPPINES 16.1.11 VIETNAM 16.1.12 REST OF ASIA PACIFIC 17 ASIA-PACIFIC API INTERMEDIATES MARKET: COMPANY LANDSCAPE 17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 18 SWOT ANALYSIS 19 COMPANY PROFILE 19.1 AUROBINDO PHARMA 19.1.1 COMPANY SNAPSHOT 19.1.2 REVENUE ANALYSIS 19.1.3 COMPANY SHARE ANALYSIS 19.1.4 PRODUCT PORFOLIO 19.1.5 RECENT DEVELOPMENTS 19.2 DIVIS LABORATORIES LIMITED 19.2.1 COMPANY SNAPSHOT 19.2.2 REVENUE ANALYSIS 19.2.3 COMPANY SHARE ANALYSIS 19.2.4 PRODUCT PORTFOLIO 19.2.5 RECENT DEVELOPMENTS 19.3 BASF SE 19.3.1 COMPANY SNAPSHOT 19.3.2 REVENUE ANALYSIS 19.3.3 COMPANY SHARE ANALYSIS 19.3.4 PRODUCT PORTFOLIO 19.3.5 RECENT DEVELOPMENT 19.4 CAMBRIX CORPORATION 19.4.1 COMPANY SNAPSHOT 19.4.2 COMPANY SHARE ANALYSIS 19.4.3 PRODUCT PORTFOLIO 19.4.4 RECENT DEVELOPMENTS 19.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG) 19.5.1 COMPANY SNAPSHOT 19.5.2 REVENUE ANALYSIS 19.5.3 PRODUCT PORTFOLIO 19.5.4 RECENT DEVELOPMENT 19.6 ACETO 19.6.1 COMPANY SNAPSHOT 19.6.2 PRODUCT PORTFOLIO 19.6.3 RECENT DEVELOPMENT 19.7 HIKAL LTD. 19.7.1 COMPANY SNAPSHOT 19.7.2 REVENUE ANALYSIS 19.7.3 PRODUCT PORTFOLIO 19.7.4 RECENT DEVELOPMENTS 19.8 ALZCHEM GROUP AG 19.8.1 COMPANY SNAPSHOT 19.8.2 REVENUE ANALYSIS 19.8.3 PRODUCT PORTFOLIO 19.8.4 RECENT DEVELOPMENTS 19.9 VERTELLUS 19.9.1 COMPANY SNAPSHOT 19.9.2 PRODUCT CATEGORIES 19.9.3 RECENT DEVELOPMENTS 19.10 SANOFI 19.10.1 COMPANY SNAPSHOT 19.10.2 REVENUE ANALYSIS 19.10.3 PRODUCT PORFOLIO 19.10.4 RECENT DEVELOPMENTS 19.11 ATUL LTD 19.11.1 COMPANY SNAPSHOT 19.11.2 REVENUE ANALYSIS 19.11.3 PRODUCT PORTFOLIO 19.11.4 RECENT DEVELOPMENTS 19.12 AARTI INDUSTRIES LIMITED 19.12.1 COMPANY SNAPSHOT 19.12.2 REVENUE ANALYSIS 19.12.3 PRODUCT PORTFOLIO 19.12.4 RECENT DEVELOPMENT 19.13 VASUDHA PHARMA 19.13.1 COMPANY SNAPSHOT 19.13.2 PRODUCT PORTFOLIO 19.13.3 RECENT DEVELOPMENT 19.14 ANYANG GENERAL CHEMICAL CO., LTD. 19.14.1 COMPANY SNAPSHOT 19.14.2 PRODUCT PORFOLIO 19.14.3 RECENT DEVELOPMENT 19.15 DISHMAN CARBOGEN AMICS LTD 19.15.1 COMPANY SNAPSHOT 19.15.2 REVENUE ANALYSIS 19.15.3 PRODUCT PORFOLIO 19.15.4 RECENT DEVELOPMENTS 19.16 GANESH-GROUP 19.16.1 COMPANY SNAPSHOT 19.16.2 PRODUCT PORTFOLIO 19.16.3 RECENT DEVELOPMENTS 19.17 LEVACHEM COMPANY LIMITED 19.17.1 COMPANY SNAPSHOT 19.17.2 PRODUCT PORFOLIO 19.17.3 RECENT DEVELOPMENT 19.18 SANDOO PHARMACEUTICALS AND CHEMICALS CO., LTD. 19.18.1 COMPANY SNAPSHOT 19.18.2 PRODUCT PORTFOLIO 19.18.3 RECENT DEVELOPMENT 19.19 SAREX 19.19.1 COMPANY SNAPSHOT 19.19.2 PRODUCT PORTFOLIO 19.19.3 RECENT DEVELOPMENTS 19.20 SUPRIYA LIFESCIENCE LTD. 19.20.1 COMPANY SNAPSHOT 19.20.2 PRODUCT PORTFOLIO 19.20.3 RECENT DEVELOPMENT 20 QUESTIONNAIRE 21 RELATED REPORTS